GLP-1s and Endometriosis: An Interesting Lead, Not a Treatment

The short version

There are no randomized trials of a GLP-1 for endometriosis. Not small ones, not preliminary ones — none. What exists is a mechanistic literature that is more interesting than that sentence suggests, and an obesity-comorbidity literature that is clinically useful right now. Anyone selling you a GLP-1 as an endometriosis treatment is ahead of the evidence by several years.

That is worth saying plainly, because the mechanistic papers are genuinely suggestive and it would be easy to read them as more than they are.

What was actually found

In 2022, researchers measured hormone and incretin levels in the peritoneal fluid of women with endometriosis and found that GLP-1 was decreased there, alongside changes in ghrelin, glucagon and visfatin². That is a real measurement in the right tissue, and it is the observation everything else builds on.

A 2026 review in the International Journal of Molecular Sciences took that finding and built a mechanistic framework from it — proposing peritoneal incretin deficiency as a target, and tirzepatide as a hypothetical multi-axis adjuvant in treatment-refractory disease³. Read the title carefully, because the authors did not hide the ball: it describes itself as a hypothesis and a mechanistic framework. It is a paper arguing that someone should run a trial, not a report of one.

The part that is actually actionable

Set the mechanism aside and there is a more immediate connection. A 2026 state-of-the-art review examined the link between endometriosis and obesity directly⁴, and a 2025 review in Reproductive Biology and Endocrinology covered medical therapy for obesity in women of reproductive age with fertility as the endpoint¹.

This is where a GLP-1 has a defensible role today, and it is an indirect one. If you have endometriosis and obesity, treating the obesity is worth doing on its own terms — for fertility if that is relevant, and for the metabolic reasons that apply to anyone. Adipose tissue is hormonally active and estrogen-producing, which gives a plausible route by which weight loss might influence an estrogen-dependent disease. Plausible. Not demonstrated.

There is also a broader inflammation thread: a 2025 review discussing meta-inflammation in chronic pain management touches the mechanisms that make people wonder about these drugs in pain conditions generally⁵. It is context, not evidence for endometriosis specifically.

What this means for a decision

A GLP-1 will not be prescribed to treat your endometriosis, and should not be. If a telehealth provider offers to, that provider is either misinformed or marketing. The prescription, if it happens, is for weight — and that is a legitimate reason on its own.

Weight loss may help your symptoms indirectly, and may not. The estrogen mechanism is reasonable and the clinical evidence connecting weight loss to endometriosis pain outcomes is not there. Expect the metabolic benefits; do not count on the pain benefits.

Do not stop endometriosis treatment. Nothing here suggests a GLP-1 substitutes for hormonal management, excision surgery, or a pain plan. The mechanistic paper explicitly frames tirzepatide as a possible adjuvant in refractory disease³ — an addition, in a hypothesis, in the hardest cases.

Watch for the symptom overlap. Endometriosis frequently comes with bloating, nausea and altered bowel habit. So do GLP-1s. If your symptoms change after starting, it will be harder to tell which cause is which — and that matters if a flare would otherwise prompt investigation. Worth knowing before you start rather than during.

What would change this

A randomized trial of a GLP-1 in endometriosis, with pain scores as an endpoint. The 2026 framework paper is essentially a case for running one³. Until it happens, the field has a plausible mechanism, one peritoneal-fluid measurement pointing in the right direction², and a real but indirect obesity link⁴.

The bottom line

If you have endometriosis and you want a GLP-1 for weight, that is a reasonable thing to want and the obesity-and-fertility literature supports it^1,4. If you want one for endometriosis, the honest answer is that the science is at the stage of proposing trials rather than reporting them³. The interesting finding — depleted GLP-1 in peritoneal fluid² — is a lead worth following. It is not a reason to pay for a prescription today.